239 related articles for article (PubMed ID: 30903351)
1. Testosterone replacement therapy is associated with an increased risk of urolithiasis.
McClintock TR; Valovska MI; Kwon NK; Cole AP; Jiang W; Kathrins MN; Bhojani N; Haleblian GE; Koehlmoos T; Haider AH; Basaria S; Trinh QD
World J Urol; 2019 Dec; 37(12):2737-2746. PubMed ID: 30903351
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
3. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
4. Medical Treatments for Hypogonadism do not Significantly Increase the Risk of Deep Vein Thrombosis Over General Population Risk.
Kavoussi PK; Machen GL; Wenzel JL; Ellis AM; Kavoussi M; Kavoussi KM; Kavoussi SK
Urology; 2019 Feb; 124():127-130. PubMed ID: 30447269
[TBL] [Abstract][Full Text] [Related]
5. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism.
Bacevičienė R; Valonytė L; Ceponis J
Medicina (Kaunas); 2013; 49(2):71-7. PubMed ID: 23888342
[TBL] [Abstract][Full Text] [Related]
6. Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism: A Retrospective Cohort Study of the Veterans Administration Database.
Sharma R; Oni OA; Chen G; Sharma M; Dawn B; Sharma R; Parashara D; Savin VJ; Barua RS; Gupta K
Chest; 2016 Sep; 150(3):563-71. PubMed ID: 27179907
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study.
Loo SY; Azoulay L; Nie R; Dell'Aniello S; Yu OHY; Renoux C
Am J Med; 2019 Sep; 132(9):1069-1077.e4. PubMed ID: 30953635
[TBL] [Abstract][Full Text] [Related]
8. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
9. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
10. Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk.
Maganty A; Osterberg EC; Ramasamy R
Am J Mens Health; 2015 Jul; 9(4):340-4. PubMed ID: 24972716
[TBL] [Abstract][Full Text] [Related]
11. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
12. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
Hackett G; Cole N; Mulay A; Strange RC; Ramachandran S
BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
[TBL] [Abstract][Full Text] [Related]
13. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
[TBL] [Abstract][Full Text] [Related]
14. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
15. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
17. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.
Sumii K; Miyake H; Enatsu N; Matsushita K; Fujisawa M
Andrologia; 2016 Mar; 48(2):198-202. PubMed ID: 25988884
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone.
Chrysant SG; Chrysant GS
Hosp Pract (1995); 2018 Apr; 46(2):47-55. PubMed ID: 29478348
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment patterns of testosterone replacement medications.
Donatucci C; Cui Z; Fang Y; Muram D
J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
